Aberrant receptor tyrosine kinase signaling plays an important role in the molecular pathogenesis of brain tumors. We have been studying a previously identified human glioblastoma-derived PDGFR-a mutant that has an in-frame deletion in the extracellular domain, causing loss of exons 8 and 9 (PDGFR-a D8,9 ). In the primary tumor, this deletion mutant receptor was shown to be amplified and overexpressed. The purpose of this study was to determine the expression, activity, localization, and transformation properties of this deletion mutant. In the absence of serum, or PDGF-AA, PDGFR-a D8,9 was phosphorylated on tyrosine residues, indicating ligandindependent autoactivation. Localization by staining and cell surface biotinylation studies revealed expression of the deletion mutant predominantly in the cytoplasm, with very little present on the cell surface. To determine if PDGFRa D8,9 was oncogenic, we transfected wild-type and mutant receptors into Rat1 cells and performed analyses of cell growth, in vitro transformation, and subcutaneous growth in the nude mouse. PDGFR-a D8,9 -expressing cells displayed enhanced cell growth and survival in low serum, and formed foci in monolayer cultures. PDGFR-a D8,9 -expressing Rat1 cells were also tumorigenic when injected subcutaneously into nude mice. Expression of PDGFRa D8,9 was also associated with increased c-Jun phosphorylation in the absence of PDGF ligand, demonstrating also that the mutant receptor is associated with altered intracellular signaling. These data demonstrate that PDGFR-a D8,9 is transforming, and it is the first demonstration of a naturally occurring tumor-derived mutant PDGFR-a with oncogenic properties.
Aberrant receptor tyrosine kinase signaling plays an important role in the molecular pathogenesis of brain tumors. We have been studying a previously identified human glioblastoma-derived PDGFR-a mutant that has an in-frame deletion in the extracellular domain, causing loss of exons 8 and 9 (PDGFR-a D8,9 ). In the primary tumor, this deletion mutant receptor was shown to be amplified and overexpressed. The purpose of this study was to determine the expression, activity, localization, and transformation properties of this deletion mutant. In the absence of serum, or PDGF-AA, PDGFR-a D8,9 was phosphorylated on tyrosine residues, indicating ligandindependent autoactivation. Localization by staining and cell surface biotinylation studies revealed expression of the deletion mutant predominantly in the cytoplasm, with very little present on the cell surface. To determine if PDGFRa D8,9 was oncogenic, we transfected wild-type and mutant receptors into Rat1 cells and performed analyses of cell growth, in vitro transformation, and subcutaneous growth in the nude mouse. PDGFR-a D8,9 -expressing cells displayed enhanced cell growth and survival in low serum, and formed foci in monolayer cultures. PDGFR-a D8,9 -expressing Rat1 cells were also tumorigenic when injected subcutaneously into nude mice. Expression of PDGFRa D8,9 was also associated with increased c-Jun phosphorylation in the absence of PDGF ligand, demonstrating also that the mutant receptor is associated with altered intracellular signaling. These data demonstrate thatIntroduction Platelet-derived growth factor (PDGF) is a secreted factor that exerts its effects by binding to a cell surface PDGF-receptor (PDGFR). PDGF-mediated signaling has an important role in the regulation of cell growth and motility as well as in development (Heldin et al., 1998; Heldin and Westermark, 1999) . PDGFRs are tyrosine kinases that have an extracellular domain consisting of five immunoglobulin(Ig)-like folds, a transmembrane domain, juxtamembrane domain, and an intracellular kinase domain. Two well-characterized polypeptide chains A and B act as disulfide-linked ligands, either as homodimers (AA, BB) or heterodimers (AB). The ligands bind and cause dimerization of PDGFRs, a or b, with all three ligands capable of binding PDGFR-a. In contrast, PDGFR-b binds PDGF-BB homodimers but not AA or AB forms. Recently, two new PDGFR ligands were identified, PDGF-C, which binds as a disulfide-linked homodimer to PDGFR-a, and PDGF-D which similarly binds specifically only to PDGFR-b (Li et al., 2000; Bergsten et al., 2001; LaRochelle et al., 2001) .
PDGF ligands and receptors play an important role in normal development. Homozygous deletion of both PDGF-A and B ligands as well as PDGF-a and -b receptors in mice causes embryonic or perinatal lethality (Leveen et al., 1994; Soriano, 1994; Bostrom et al., 1996; Lindahl et al., 1997; Soriano, 1997) . PDGF/PDGFRa signaling plays a particularly important role in the brain development. The PDGFR-a-null mice show nervous system defects with abnormalities in the neural tube and brain (Soriano, 1997) . Allele-specific PDGFR-a knockin mice, which harbour mutations in specific regions for activation of phospatidylinositol-3 (PI3)-kinase or Src family kinases, indicate that PI3-kinase pathways have a predominant role in PDGFR-a function during development, as these PDGFR-a-PI3-kinase signaling-deficient animals exhibit neonatal lethality with defects similar to PDGFR-a-null mice (Klinghoffer et al., 2002) . The Src family kinase mutants are born but quickly develop neurologic signs caused by hypomyelination from decreased numbers and decreased migration of oligodendrocyte progenitor cells. The PDGF-A knockout also demonstrates severe depletion of oligodendrocytes (Fruttiger et al., 1999) . Interestingly, increased number of oligodendrocyte progenitors are formed and found in aberrant locations in transgenic mice overexpressing PDGF-A ligand in the brain (Calver et al., 1998) .
Aberrant expression of PDGF ligands or receptors is well described in neoplasia. The transforming protein product of the v-sis gene of simian sarcoma virus was discovered to be identical to PDGF-B (Doolittle et al., 1983; Waterfield et al., 1983) . Both v-sis and c-sis can transform NIH 3T3 fibroblasts in culture (Clarke et al., 1984; Bejcek et al., 1992) . PDGF-A can transform NIH 3T3 cells (Kim et al., 1994) , although not as potently as PDGF-B (Bergsten et al., 2001) . PDGFR-b has been directly implicated in cancer in a number of studies. It was discovered as a fusion gene product in a chronic myelogenous leukemia, where the tyrosine kinase domain was coupled to the ets gene, tel (Carroll et al., 1997; Jousset et al., 1997) . This fusion protein, however, was not capable of transforming NIH 3T3 fibroblasts, suggesting that it functions differently from a hyperactive wild-type receptor. PDGFR-b has also been suggested to be a target for the E5-transforming protein of the bovine papilloma virus, as E5 has been shown to bind to and cause ligand-independent activation of the b-receptor (Petti et al., 1991 (Petti et al., , 1997 DiMaio, 1992, 1994) . In vitro, wild-type PDGFR-b expression in NIH 3T3 fibroblasts is transforming (Uren et al., 1996; DeMali et al., 1997) as is wild-type PDGFR-a, although with lower potency (Yu et al., 1994a) . Despite the oncogenic potential of these receptors, hyperactive and oncogenic mutants from human tumors have yet to be reported.
Expression studies of PDGF ligand and receptors in brain tumors have shown that overexpression of PDGF ligands and receptors, including PDGF-A, PDGFR-a, and PDGFR-b, occurs in high-grade poorly differentiated gliomas (Nister et al., 1988 (Nister et al., , 1991 Fleming et al., 1992; Kumabe et al., 1992; Westermark et al., 1995; Kirsch et al., 1997) . Recent data suggest that expression of PDGFR-a seems to be particularly common in tumors of the oligodendrocyte lineage (oligodendrogliomas) with increased expression demonstrated in 17/17 (Di Rocco et al., 1998 ) or 7/7 (Shoshan et al., 1999 tumor specimens studied by immunohistochemistry. Injection of a wild-type PDGF-B-ligand-expressing retrovirus into the brain induces the formation of brain tumors with a variety of phenotypes (Uhrbom et al., 1998) . Targeted expression of PDGF-A to mouse neural progenitors or astrocytes induces lesions reminiscent of oligodendrogliomas or oligoastrocytomas (Dai et al., 2001) . Although an increase in the expression of the PDGFR-a in brain tumor specimens and cell lines has been reported in scattered samples of a variety of different types of brain tumors, the mechanism by which PDGFR-a overexpression contributes to brain tumorigenesis has not been determined.
Here, we report studies on mutant PDGFR-a (PDGFR-a D8,9 ) that was previously isolated from a glioblastoma specimen (Kumabe et al., 1992) . The mutant PDGFR-a has an in-frame 81-amino-acid deletion in the extracellular domain with retention of normal transmembrane and intracellular domains (D375-455) (Figure 1) . The in-frame deletion of 243 base pairs (bp), resulting from a complete loss of PDGFR-a gene exons 8 and 9, creates a novel transcript fusing exons 7-10 resulting in loss of coding regions for part of the fourth and fifth Ig-like domains. Interestingly, this type of deletion is reminiscent of the oncogenic deletion frequently observed in human glioblastomas, which generates a constitutively active EGFRvIII protein (Sugawa et al., 1990; Ekstrand et al., 1992; Nishikawa et al., 1994; Batra et al., 1995; Huang et al., 1997; Holland et al., 1998; Feldkamp et al., 1999) . It is presently completely unknown if the increased PDGFR-a expression observed in previous PDGFR mRNA and protein expression studies of primary brain tumor specimens is associated with expression of similar mutant PDGFR-a forms. The PDGFR-a deletion is small, and may not be detectable by the Northern or Western analyses done in these previous studies. Therefore, the prevalence of this PDGFR-a gene alteration in gliomas is unknown as it has not been carefully studied. We demonstrate that the deletion mutant receptor PDGFR-a D8,9 is aberrantly activated and localized, and is also capable of transforming Rat1 cells.
Results

PDGFR-a
D8,9 has altered migration on SDS-PAGE and is active in the absence of ligand In order to characterize expression and activity of the mutant PDGFR-a receptor, we transiently transfected Cos-7 cells with wild-type and mutant PDGFR cDNA (PDGFR-a D8,9 ) and performed Western blot analysis. Untransfected Cos-7 cells do not express detectable Figure 2a (bottom panel) demonstrates that in the absence of ligand, the wild-type PDGFR-a migrates as a doublet at 170-185 kDa and the mutant receptor migrates as a single band on a Western blot at 165 kDa. To assess the activity of these PDGFR-a receptors, the transfected Cos-7 cell lysates were analysed on Western blots by probing with an antibody against phosphorylated tyrosine in the presence and absence of PDGF-AA ligand. Figure 2a (top panel) shows that the mutant receptor is aberrantly phosphorylated on tyrosine residues in the absence of ligand and does not undergo an increase in tyrosine phosphorylation after 5 min stimulation with PDGF-AA. The results from three independent transfections are shown in the histogram in Figure 2b , which demonstrates the amount of tyrosine phosphorylated protein normalized to PDGFR-a expression for wild-type and mutant receptor in stimulated and unstimulated cells. These results clearly show that PDGFR-a D8,9 is aberrantly tyrosine phosphorylated in the absence of ligand (P ¼ 0.02).
While the deletion of coding sequences within the extracellular domain of the mutant does not remove potential glycosylation sites, it is possible that altered migration of the mutant is at least partially affected because of defective processing. In the endoplasmic reticulum, PDGFR-a undergoes post-translational glycosylation on asparagine residues. The first N-linked sugar modification can be inhibited by tunicamycin. Cos-7 cells transfected with wild-type PDGFR-a and PDGFR-a D8,9 were treated with tunicamycin for 24 h prior to lysis, and these lysates were then subjected to Western analysis using a PDGFR-a antibody directed against the C-terminus. Figure 3 shows that the wildtype PDGFR-a is shifted from a doublet at 170-185 kDa to a single band at 160 kDa following tunicamycininduced inhibition of N-linked glycosylation. PDGFRa D8,9 is shifted from 165 to 145 kDa after tunicamycin treatment, indicating that this receptor is N-linked glycosylated and that the deletion of 81 amino acids is mostly responsible for its faster migration.
D8,9 is predominantly located in the cytoplasm and not the plasma membrane
We next studied the subcellular localization of the receptor by immunocytochemistry and confocal microscopy following transfection of Cos-7 cells with wildtype and the deleted mutant receptor. Immunofluorescence staining was performed with an amino terminal (aa150-189) PDGFR-a antibody in unpermeabilized and permeabilized cells. As shown in Figure 4 , staining for the wild-type receptor in unpermeabilized cells reveals abundant cell surface staining, whereas the deleted mutant receptor demonstrates very little detectable cell surface staining. Following permeabilization, the cells expressing wild-type PDGFR-a showed cell Figure 2 PDGFR-a D8,9 is autophosphorylated in the absence of ligand. (a) A representative Western blot shows that Cos7-transfected PDGFR-a D8,9 has elevated autophosphorylation in low serum compared to PDGFR-a. Post-transfection, all cells were switched to media containing 0.5% fetal bovine serum for 18 h prior to PDGF treatment and lysis. Cells were treated with PDGF-AA (100 ng/ml final) for 5 min prior to lysis as indicated. Phosphotyrosine was detected on Western blot using mouse antiphosphotyrosine antibody. The same blot was stripped and reprobed with rabbit anti-PDGFR-a antibody. (b) Histogram of densitometry analyses of independent Western blots from three Cos7 transfection experiments performed as in (a). PDGFR-a D8,9
shows 2.0-fold increased autophosphorylation compared to wild type in low serum. The pTyr levels are shown normalized to the level of PDGFR-a. The results are expressed as mean 7s.d. Statistical significance, compared to serum-starved wild type, was determined by t-tests and indicated above each bar in the graph Figure 3 PDGFR-a D8,9 undergoes N-linked glycosylation. Inhibition of N-linked glycosylation reduced PDGFR-a size from a doublet at 170 and 185 kDa to a single band at 160 kDa. PDGFRa D8,9 was reduced in size from 165 to 145 kDa. Cos-7 cells were transfected with control plasmid, PDGFR-a, or PDGFR-a D8,9 . Cells were treated with tuniamycin for 24 h prior to lysis as described in Materials and methods. PDGFR-a was detected on Western blot using rabbit anti-PDGFR-a (C-terminal) Figure 4 PDGFR-a D8,9 is localized intracellularly rather than on the cell surface. Cos7 cells were transfected with control plasmid, PDGFR-a, or PDGFR-a D8,9 and stained with mouse PDGFR-a recognizing the extracellular domain (aa 150-189, Clone R1). Unpermeablized cells were stained prior to fixation, washed with PBS, and then fixed with paraformaldehyde. Permeabilized cells were fixed with paraformaldehyde and permeabilized with Triton-X100 prior to staining. Cells were viewed on a laser scanning confocal microscope surface and cytoplasmic staining but the mutant PDGFR-a had only cytoplasmic staining.
These immunostaining studies demonstrate that there is a paucity of expression of PDGFR-a D8,9 at the plasma membrane. To further confirm this finding, Cos-7 cells transfected with mutant and wild-type PDGFR-a were subjected to cell surface biotinylation and then immunoprecipitation with PDGFR-a antibodies. Figure 5 demonstrates that the C-terminal antibody pulls down equivalent amounts of the wild-type and mutant receptor (lanes 2 and 3, bottom panel). The cell surface PDGFR-a was identified by probing the identical PDGFR-a immunoprecipitates with strepavidin-HRP. This experiment demonstrates that very little of mutant PDGFR-a is biotinylated (lane 3, upper panel) compared to wild type (lane 2, upper panel). Together with the immunostaining studies, this experiment indicates that few mutant receptors are located at the cell surface, suggesting that they are either inefficiently transported to the cell surface or are rapidly endocytosed once at the cell surface.
D8,9 provides a survival and growth advantage over wild type
We next wanted to determine if PDGFR-a D8,9 provided a growth advantage over wild-type PDGFR-a in vitro. NIH 3T3 cells were chosen for analysis of cell growth because they are dependent on PDGF ligand for growth and have been well characterized for analysis of PDGFR transformation (Bejcek et al., 1992; Uren et al., 1996) . Stably transfected NIH 3T3 cells with wild-type or mutant PDGFR-a were bulk selected to avoid clonal variation. Transfected cells were subjected to growth in low serum (0.5%) or 10% serum and a cell proliferation assay (MTT assay, see Materials and methods) was performed. As shown in Figure 6 , in both low serum and 10% serum, expression of the PDGFR-a D8,9 is associated with a survival advantage compared to control cells and compared to cells expressing wild-type receptor. We have confirmed these results by counting of cell numbers in independent and replicate plates of wild-type and mutant transfected cells over the same time period (data not shown).
D8,9 leads to an increase in c-Jun phosphorylation
To determine if the growth advantage associated with PDGFR-a D8,9 expression was related to an alteration in intracellular signal transduction, we performed an assay for c-Jun activation in PDGFR-a and PDGFR-a D8,9
transfected NIH 3T3 cells. c-Jun is a component of the AP-1 complex and its activation has been implicated in oncogenic transformation (Whitmarsh and Davis, 1996; Ip and Davis, 1998; Vogt, 2001) . We used an assay to determine c-Jun activation by phosphorylation (PathDirect, Strategene), which consists of a two-plasmid trans-reporter system (Figure 7) . On the trans-activator plasmid the c-Jun activation domain is fused to the Gal4 DNA-binding domain and expressed under a CMV promoter. The reporter plasmid has tandem Gal4 DNAbinding sites located upstream from the luciferase gene. Luciferase expression is then correlated with phosphorylation of the activation domain of c-Jun. NIH 3T3 cells expressing PDGFR-a and PDGFR-a D8,9 were cotrans- Figure 5 Cell surface biotinylation confirms that PDGFR-a D8,9 is not predominantly present on the cell surface. For equivalent amounts of immunoprecipitated PDGFR-a protein (lower panel), very little labeled PDGFR-a D8,9 can be detected on the cell surface compared to PDGFR-a (upper panel). Cos-7 cells were transfected with PDGFR-a or PDGFR-a D8,9 and the cell surface proteins were biotin labeled as described in Materials and methods. All extracts were immunoprecipitated with rabbit anti-PDGFR-a C-terminal epitope. Biotinylated proteins were detected using streptavidin-linked-horseradish peroxidase. PDGFR-a was detected with rabbit anti-PDGFR-a (C-terminal) fected with the PathDirect reporting system. In the absence of ligand, PDGFR-a D8,9 caused a 2.5-fold increase in luciferase activity compared to wild-type transfected cells. These results demonstrate that PDGFR-a D8,9 causes an increase in c-Jun activation in the absence of ligand.
PDGFR-a D8,9 transforms Rat1 cells in vitro and causes growth of tumors in nude mice
We next tested if the mutant receptor was transforming in vitro and in vivo. Rat1 cells were transfected with wildtype PDGFR-a and PDGFR-a D8,9 and bulk selected to avoid clonal variation. Immediately after selection, cells were plated in replicates of three and cultured for 21 days with frequent media changes to score for the appearance of colonies of noncontact-inhibited transformed cells growing on top of the monolayer. H-ras was also transfected as a positive control. H-ras transfected Rat1 cells formed many hundreds of colonies (data not shown). As shown in Figure 8 , Rat1 cells expressing PDGFR-a D8,9 demonstrated a significant increase in the formation of noncontact-inhibited colonies compared to wild-type expressing cells and negative controls transfected with empty plasmid. Finally, stably transfected Rat1 cells expressing PDGFR-a D8,9 or wild-type PDGFR-a were implanted subcutaneously into the flank of nude mice to determine if these cells were tumorigenic in vivo. Six nude mice were each injected with 10 6 Rat1 cells expressing wildtype (left flank) or PDGFR-a D8,9 (right flank). The weights of individual tumors are shown in Table 1 . The tumor masses formed by Rat1 cells expressing mutant PDGFR-a were between 2 and 12-fold greater than wild type (mean 5.9-fold greater, P ¼ 0.05), suggesting that the deletion mutant receptor is more potent at transforming Rat1 cells compared to its wild-type counterpart.
Discussion
Activating mutations in receptor tyrosine kinases occur commonly in cancer. The mechanism by which the mutant receptor tyrosine kinases contribute to neoplasia is not fully understood. Mutations or intragenetic deletions may affect intracytoplasmic tyrosine phosphorylation of the receptor and kinase activity, or may effect subcellular localization, which in turn may affect the activation of downstream substrates. It is of interest that v-sis/c-sis is capable of transforming cells without being secreted, causing activation of a pool of intracellular PDGFR (Bejcek et al., 1989 (Bejcek et al., , 1992 Valgeirsdottir et al., 1995) . The purpose of this study was to characterize the expression, activity, and localization of a human brain tumor-derived PDGFR-a deletion mutant in order to determine whether it was selected on the basis of increased transformation potential. This study is the first demonstration that a human tumorderived mutant of PDGFR-a is capable of cell transformation and suggests that the mutant receptor is aberrantly localized and activated in the cell. Figure 6 PDGFR-a D8,9 provides a growth advantage in both low and high serum. NIH 3T3 cells were transfected with PDGFR-a, and PDGFR-a D8,9 and bulk selected in 1000 mg/ml G418 for 1 week to avoid clonal variation. Control NIH 3T3 cells (solid circle) and bulkselected NIH 3T3 cells expressing PDGFR-a (open circle) and PDGFR-a D8,9 (solid triangle) were cultured in their normal media containing 10% (a) or 0.5% (b) calf serum as described in Materials and methods. Cell proliferation was determined using an MTT assay as described in Materials and methods and expressed as mean (n ¼ 6) optical density units. Error bars are 1 s.d. P-values were determined using paired t-tests comparing PDGFR-a-to PDGFR-a D8,9
-expressing cells
Transformation by a PDGFR-a mutant ID Clarke and PB Dirks (Nister et al., 1988 (Nister et al., , 1991 Fleming et al., 1992; Kumabe et al., 1992; Westermark et al., 1995; Kirsch et al., 1997) . These studies have not determined whether deleted forms of PDGFR-a exist because small deletions in the receptor may not affect the analysis of transcripts by Northern blot. Identification of a deleted form of PDGFR-a in a malignant tumor, where it was amplified and overexpressed, suggests that PDGFR-a may contribute to brain tumorigenesis by mechanisms other than overexpression. The importance of PDGF signaling in brain tumorigenesis has recently been supported by two studies where retroviral injection of PDGF ligand into the mouse brain led to proliferative lesions reminiscent of oligodendrogliomas, a common type of primary brain tumor (Uhrbom et al., 1998; Dai et al., 2001) .
Deletion of one-half of the fourth and one-half of the fifth immunoglobulin-like domains is not predicted to alter the ligand-binding ability of PDGFR-a D8,9 , as this deletion does not affect the ligand-binding IG-like domains D2-3 (Yu et al., 1994b; Lokker et al., 1997) . A previously studied and constructed deletion mutant of PDGFR-a (D375-450), with a similar deletion to the tumor-derived PDGFR-a D8,9 mutant, but only containing the extracellular domain, is capable of binding ligand in an in vitro binding assay, but with a reduction in efficiency compared to wild type (Yu et al., 1994b) . The IG-like domain 4 is thought to be involved in receptor dimerization and not ligand binding (Omura et al., 1997) . showed a 10-fold more foci than cells expressing PDGFR-a. Rat1 cells were transfected with PDGFR-a, PDGFR-a D8,9 or control plasmid and bulk selected in 1000 mg/ml G418 for 1 week to avoid clonal variation. Immediately after selection, cells were used for focus density assay as described in Materials and methods. Foci were stained and counted after 3 weeks. The data are given as mean foci per well (n ¼ 6). Error bars are 1 s.d. P-values were determined using paired t-tests comparing PDGFR-a-to PDGFR-a D8,9
-expressing cells In Cos-7 cells that do not express any endogenous receptor, PDGFR-a D8,9 is tyrosine phosphorylated in the absence of PDGF-AA, demonstrating that the receptor is active, independent of ligand stimulation. This deleted receptor runs as a single band in the presence or absence of PDGF-AA stimulation, in contrast to the wild-type receptor, which runs as a doublet. The single band suggested that the mutant receptor may not be processed properly in the endoplasmic reticulum and golgi by glycosylation, even though the deletion did not cause loss of asparagine residues predicted to be modified by glycosylation. Western analysis following inhibition of N-linked glycosylation with tunicamycin suggested that the mutant receptor at least is partially glycosylated, although we have yet to determine whether the mutant receptor undergoes higher order sugar modification in the golgi apparatus. If the receptor is improperly processed in the golgi, it may not arrive at the cell membrane where it is believed to exert its main function. Cell staining experiments indicated that the deletion mutant receptor was barely detectable at the cell surface, but was localized inside the cell, in contrast to wild-type receptor that was highly expressed at the surface. Cell surface biotinylation experiments were consistent with the staining experiments that revealed little mutant receptor at the cell surface. Binding studies by Yu et al. (1994b) have suggested that a constructed D375-450 PDGFR-a (with a similar but nonidentical extracellular deletion to PDGFR-a D8,9 ) had some cell surface expression, but our data support that PDGFRa D8,9 is predominantly cytoplasmic. PDGFR-a has previously been shown to be capable of weakly transforming NIH 3T3 cells in vitro (Yu et al., 1994a; Uren et al., 1996) . We now show that the tumorderived PDGFR-a D8,9 is more potent than wild-type receptor in the stimulation of growth of NIH 3T3 cells in low serum conditions, is able to transform Rat1 cells in a focus-density assay, and produces larger tumors when implanted into the flanks of nude mice. These results suggest that the mutant PDGFR-a is an oncogene. The activating extracellular deletion in PDGFR-a in a brain tumor is reminiscent of the alteration in EGFR, the EGFRvIII, that plays an important role in human glioblastoma pathogenesis (Sugawa et al., 1990; Ekstrand et al., 1992; Nishikawa et al., 1994; Batra et al., 1995; Huang et al., 1997; Holland et al., 1998; Feldkamp et al., 1999; Bachoo et al., 2002) .
Finally, we also suggest that in the absence of ligand, PDGFR-a D8,9 causes increased phosphorylation of c-Jun compared to wild type, suggesting that it is able to signal in the absence of ligand. Although the exact role of cJun in oncogenic transformation is not well understood, replacement of a normal c-Jun allele with an unphosphorylatable amino-terminal mutant c-Jun allele reduced v-ras-and v-fos-mediated transformation both in vitro and in vivo (Behrens et al., 2000) . In addition, cJun-null fibroblasts are resistant to Ras transformation (Johnson et al., 1996) .
In conclusion, in addition to showing the transforming properties of the mutant receptor, these studies suggest a number of possible mechanisms by which the mutant receptor may promote brain tumorigenesis. In the absence of the ligand, the mutant receptor is phosphorylated on tyrosine residues suggesting that it is constitutively activated. This constitutive activation of the receptor may lead to continual stimulation of downstream signaling pathways. The abundance of localization to the cytoplasm suggests that by virtue of its location, there may be activation of distinct downstream signaling intermediates. Further studies of the mechanisms of signaling of the mutant receptor may lead to a better understanding of its oncogenic function.
Materials and methods
PDGFR expression plasmids
The cDNAs for human PDGFR-a and PDGFR-a D8,9 were a generous gift from Dr Tokuo Yamamoto, Tohoku University. The cDNAs were cloned into the pIRES2-EGFP expression plasmid (Clonetech).
Antibodies
Two anti-PDGFR-a antibodies were used. The mouse monoclonal Clone R1 (BD-Pharmingen) recognizes the Ig-like domain 2 (extracellular domain, amino acids 150-189). The rabbit anti-PDGFR-a C-terminal polyclonal (BD-Pharmingen or Upstate Biotechnology) recognizes a C-terminal epitope (amino acids 951-1089). For phosphotyrosine Western blots, mouse antiphosphotyrosine was used (Upstate Biotechnology; clone 4G10). Secondary antibodies were goat antirabbit-HRP, or goat antimouse-IgG-HRP (Sigma) and goat antimouseIgG-Texas Red (Jackson ImmunoResearch).
Cell culture
Cos-7 (ATCC CRL-1651) and Rat-1 cells were cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum, 4 mm l-glutamine, 4.5 g/l glucose and 1.0 mm sodium pyruvate. NIH 3T3 cells (ATCC CRL-1658) were cultured in DMEM supplemented with 10% heat-inactivated calf serum, 4 mm l-glutamine, and 4.5 g/l glucose. Transfections were Rat1 cells were transfected with PDGFR-a or PDGFR-a D8,9 plasmids and bulk selected with 1000 mg/ml G418 for 1 week to avoid clonal variation. Immediately after selection, Rat1 cells expressing PDGFR-a or PDGFR-a D8,9 were transplanted into each flank of nude mice as described in Materials and methods. Xenografts were removed after 6 weeks and weighed. a Error is expressed as s.e.m. and P=0.05 using an unpaired t-test performed using Fugene-6 (Roche Diagnostics) according to the manufacturers' protocols and protein lysates were prepared 48 h after transfection. Cos-7 and NIH 3T3 cells were switched to 0.5% serum overnight prior to lysis for luciferase assays or phosphotyrosine Western blots as indicated. Cells were treated with 100 ng/ml PDGF-AA (Upstate Biotechnology) after serum deprivation for 14-16 h where indicated. Stable cell lines of Rat-1 and NIH 3T3 cells were bulk selected in 100 mg/ml G418 prior to focus formation assays, proliferation assays, and transplant into nude mice.
Western blots
Cells were washed in ice-cold PBS and lysed in ice-cold lysis buffer (50 mm Tris pH ¼ 7.4, 1% NP-40, 0.25% sodium deoxycholate, 0.15 m NaCl, 1 mm EDTA; 1 mm Na 3 VO 4 , 1 mm NaF, with Completet protease inhibitor tablets: Roche Diagnostics). Lysates were centrifuged at 20 000 g for 10 min at 41C and the supernatants were stored at À801C. Protein concentrations were determined using the Biorad DC protein assay. Cell lysates (50-100 mg) separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes (Immobilon-P, Millipore), blocked either 1 h at room temperature or overnight at 41C in blocking buffer (1 Â TBS; 0.1% Tween-20; and either 5% nonfat milk for anti-PDGFRa or 3% BSA for antiphosphotyrosine blots). Primary antibody incubation was performed for 1 h at room temperature in the blocking buffer. Membranes were washed and secondary antibody incubation was for 1 h at room temperature. The blots were washed and protein detected with Renaissancet chemiluminescent reagent (NEN).
Immunoprecipitations
Cell lysates (500 mg-1 mg) were incubated with 1-2 mg primary antibody mixing overnight at 41C, using rabbit anti-PDGFR-a C-terminal (Upstate Biotechnology). In total, 100 ml of a 50% slurry or Protein-A agarose (Sigma) was added and mixing continued for 2 h at 41C. The agarose was collected by centrifugation and washed three times with lysis buffer. A total of 50 ml of SDS loading buffer was added to the agarose beads and the sample was heated to 1001C for 10 min. The sample was then separated by SDS-PAGE and Western blotted as above.
Inhibition of N-linked glycosylation
Cos-7 cells were transfected for 18 h as described above. The cells were then switched into media containing 3 mg/ml tunicamycin (Roche Diagnostics) for an additional 24 h prior to cell lysis.
Cell surface protein biotinylation
Cos-7 cells were transfected as described above. The cells were washed three times in ice-cold PBS 48 h after transfection. Cells were then incubated in PBS containing 0.5 mg/ml EZLinkt Sulfo-NHS-Biotin (Pierce) for 30 min at room temperature. Cells were washed three times in ice-cold PBS and immediately used to prepare protein lysates. Immunoprecipitates were performed as described above and biotinylated proteins were detected on Western blots using streptavidinlinked horseradish peroxidase (Pierce).
Immunocytochemistry
Cos-7 cells were grown on sterile coverslips or chamber slides and transfected as described above. The cells were washed in PBS 48 h after transfection. Unpermeabilized cells were incubated with primary antibody in PBS for 30 min at room temperature (Rabbit anti-PDGFR-a extracellular domain, BD-Pharmingen). These cells were then washed and fixed with 4% paraformaldehyde. Cells were washed in PBS and incubated with secondary antibody (goat anti-Rabbit-Texas Red, Jackson ImmunoResearch) for 1 h at room temperature. Permeabilized cells were fixed with 4% paraformaldehyde, and permeabilized with Triton X-100. Cells were blocked in PBS with 10% normal goat serum for 1 h at room temperature and stained with primary antibody (Rabbit anti-PDGFRa extracellular domain, BD-Pharmingen) for 1 h at room temperature. Cells were washed and stained with secondary antibody as for unpermeabilized cells. Coverslips were mounted in ProLongt Antifade (Molecular Probes) containing 0.5 g/ml DAPI (Sigma) and imaged using a Zeiss laser scanning confocal microscope.
c-Jun trans-activation assay NIH 3T3 cells were plated onto 24-well dishes at 5 Â 10 4 cells/ well. c-Jun phosphorylation assay was performed using the 'PathDetect in vivo signal transduction pathway trans-reporting system' (Strategene). Each well was transfected with Fugene-6 (Roche) for 18 h, with 300 ng pFR-Luc, 17 ng pFA-cJun, 3 ng pRL-SV40 (Promega), and 200 ng of control or PDGFR-a expression plasmids. Media was changed to 0.5% serum750 ng/ml PDGF-AA for an additional 24 h prior to lysis for dual Renella/Luciferase assays. Three replicate transfections were performed for each sample set and the data are presented as means7s.d. P-values were determined using paired, single tailed t-tests.
Focus formation assays
Rat-1 cells were transfected with PDGFR-a and PDGFR-a D8,9 and a control plasmid, then bulk selected to avoid clonal variation for 10 days in 1000 mg/mg G418. Selected cells were plated at 5 Â 10 4 cells per well, in six-well plates. Cells were grown for 3 weeks with media changes every 2 days. After 3 weeks, foci were examined for EGFP expression and the dishes were stained in Crystal Violet. Foci were counted and expressed as mean foci/well (n ¼ 6)7s.d. P-values were determined using paired, single tailed t-tests.
Growth curves
NIH 3T3 cells were transfected with PDGFR-a and PDGFRa D8,9 and a control plasmid, then bulk selected to avoid clonal variation for 10 days in 100 mg/mg G418. Selected cells were plated at 200 cells per well in 100 ml/well in 96-well plates (replicates of six for each time point) and grown overnight in DMEM with 10% calf serum. The cells were then washed in PBS and switched to media containing either 10% calf serum or 0.5% calf serum, this was considered day zero. Viable cells were assayed using an MTT cell proliferation kit (Roche Diagnostics) on days 0, 4, 5, 6, and 7 according to the manufacturers' protocols. Briefly, on the day of assay 10 ml of MTT solution was added to each well and incubated at 371C for exactly 4 h. The reaction was stopped by adding 100 ml of solubilization buffer and the precipitated formazan salts were solubilized overnight at 371C. The plates were read in a tunable ELISA reader at 575 nm. The data are expressed as mean7s.d. P-values were determined using paired, single tailed t-tests.
Growth of tumors in nude mice
1 Â 10 6 Rat-1 cells expressing either PDGFR-a or PDGFRa D8,9 were injected subcutaneously in the flanks of six Balb/cnude mice. Each mouse was injected with PDGFR-a-expressing cells in the left flank and PDGFR-a D8,9 expressing cells in the right flank. Mice were monitored weekly and killed after 6 weeks. The tumor was removed and weighed. The data are expressed as mean 7 s.d. P-values were determined using unpaired, single tailed t-tests.
